Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Dramatic responses to checkpoint inhibitor therapy have been demonstrated in renal cell carcinoma and bladder cancer with recent Food and Drug Administration approvals in both indications. No benefit to checkpoint inhibitor therapy has yet been shown for the management of prostate cancer. Therapeutic cancer vaccines have also shown benefit in the treatment of genitourinary malignancies, specifically in the treatment of prostate cancer. Despite advances in these therapeutic modalities, benefit is limited to a subset of patients. SUMMARY:
|
Authors | Max M Wattenberg, Lawrence Fong, Ravi A Madan, James L Gulley |
Journal | Current opinion in urology
(Curr Opin Urol)
Vol. 26
Issue 6
Pg. 501-7
(11 2016)
ISSN: 1473-6586 [Electronic] United States |
PMID | 27471994
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Cancer Vaccines
(therapeutic use)
- Carcinoma, Renal Cell
(immunology, therapy)
- Humans
- Immunotherapy
(trends)
- Male
- Prostatic Neoplasms
(immunology, therapy)
- Urinary Bladder Neoplasms
(immunology)
- Urogenital Neoplasms
(immunology, therapy)
|